← Back to Investors

SR One

SR One is one of the longest-standing life sciences venture capital firms, originally founded as the venture arm of GlaxoSmithKline. Now operating as an independent firm, SR One invests globally in innovative biopharmaceutical companies developing breakthrough therapies across therapeutic areas.

Location
Philadelphia, Pennsylvania, USA & London, UK
Founded
1985
AUM
$1.5B+
Investment Range
$5M - $50M
Focus
biotech-focused
Fund Stages
seed, series-a, series-b, series-c

Investment Thesis

SR One invests in innovative life sciences companies developing transformative therapies that can significantly impact patient outcomes. With roots in big pharma, they bring deep scientific expertise and industry connections to portfolio companies. They focus on novel biology, differentiated therapeutic approaches, and experienced management teams.

Team

Partners / Managing Directors

  • Simeon George, MD - CEO & Managing Partner
  • Rajeev Dadoo, PhD - Managing Partner
  • Matthew Foy, PhD - Partner
  • Stephen Bloch, PhD - Partner

Other Key Team Members

  • Christiana Stamoulis, PhD - Partner
  • Daniel Grau - Principal

Focus Areas

  • Oncology
  • Immunology
  • Rare Diseases
  • Neuroscience
  • Gene & Cell Therapy
  • Next-Generation Therapeutics

Notable Portfolio Companies

  • Beam Therapeutics - Base editing (IPO 2020)
  • Magenta Therapeutics - Stem cell transplant conditioning
  • Nuvalent - Precision oncology (IPO 2021)
  • Arvinas - Protein degradation (IPO 2018)
  • Kymera Therapeutics - Targeted protein degradation (IPO 2020)

Notable Exits

  • Beam Therapeutics - IPO (2020, NASDAQ: BEAM)
  • Nuvalent - IPO (2021, NASDAQ: NUVL)
  • Arvinas - IPO (2018, NASDAQ: ARVN)
  • Aileron Therapeutics - IPO (NASDAQ: ALRN)
  • Anacor Pharmaceuticals - Acquired (2016, acquired by Pfizer for $5.2B)

Sources